Glenmark Pharmaceuticals is currently trading at Rs. 538.65, up by 6.00 points or 1.13% from its previous closing of Rs. 532.65 on the BSE.
The scrip opened at Rs. 529.15 and has touched a high and low of Rs. 540.00 and Rs. 529.15 respectively. So far 42438 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 973.10 on 07-Feb-2017 and a 52 week low of Rs. 530.45 on 07-Dec-2017.
Last one week high and low of the scrip stood at Rs. 572.40 and Rs. 530.45 respectively. The current market cap of the company is Rs. 15212.53 crore.
The promoters holding in the company stood at 46.53%, while institutions and non-institutions held 38.56% and 14.92% respectively.
Glenmark Pharmaceuticals, a global pharmaceutical company, has announced that the first patient has been dosed in a Phase 1 trial of GBR 1342 (NCT03309111), an investigational bispecific antibody. This first-in-human, open-label study’s primary objective is to assess the safety and tolerability of increasing doses of GBR 1342 in multiple myeloma patients until a maximum tolerated dose is reached. Additional study objectives include assessment of biomarkers, immunogenicity and additional measures of anti-tumor activity.
GBR 1342 simultaneously targets CD38, as well as the CD3 T cell co-receptor. CD38 is an antigen target implicated in multiple myeloma and other malignancies of hematopoietic origin, as well as a variety of solid tumors.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1511.55 |
Dr. Reddys Lab | 6263.70 |
Cipla | 1406.25 |
Zydus Lifesciences | 948.20 |
Lupin | 1615.50 |
View more.. |